Adapt Pharma Operations Limited et al. v. Teva Pharmaceuticals USA, Inc. et al.
stayed- Docket:
- 2:18-cv-05752
- Filed:
- 2018-04-09
- Terminated:
- 2022-07-27
π Adapt Pharma Operations Limitedπ Adapt Pharma Inc.π Adapt Pharma Limitedπ Opiant Pharmaceuticals, Inc.Δ Teva Pharmaceuticals USA, Inc.Δ Teva Pharmaceuticals Industries Ltd.
Hatch-Waxman/ANDA suit filed by Adapt Pharma and Opiant against Teva, triggered by Teva's Paragraph IV notice regarding ANDA No. 211561 for generic NARCAN 2 mg/spray. The case asserted U.S. 9,480,644 and U.S. 9,707,226. On July 28, 2020, the court stayed the case pending resolution of the related 4 mg Naloxone Case appeal; the final docket entry is dated July 27, 2022.